Publicaciones en colaboración con investigadores/as de Complejo Hospitalario de Toledo (7)

2022

  1. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

    Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34

  2. Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group

    Clinical Genitourinary Cancer, Vol. 20, Núm. 4, pp. 388.e1-388.e10

2021

  1. Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.

    OncoImmunology, Vol. 10, Núm. 1

2017

  1. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib

    Scientific Reports, Vol. 7

2015

  1. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: A retrospective cross-sectional analysis

    BMC Cancer, Vol. 15, Núm. 1

2014

  1. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma

    Cancer Chemotherapy and Pharmacology, Vol. 73, Núm. 6, pp. 1095-1107

  2. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice

    BMC Cancer, Vol. 14, Núm. 1